Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination

Alba Fresco-Taboada; Marga García-Durán; Cristina Aira; Lissett López; Patricia Sastre; Lia van der Hoek; Marit J. van Gils; Philip J.M. Brouwer; Rogier W. Sanders; Barbara Holzer; Irene Zimpernikc; Eduardo López-Collazo; Patricia Muñoz; Paloma Rueda; Carmen Vela

doi:10.1016/j.diagmicrobio.2022.115650

Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination

Alba Fresco-Taboada, Marga García-Durán, Cristina Aira, Lissett López, Patricia Sastre, Lia van der Hoek, Marit J. van Gils, Philip J.M. Brouwer, Rogier W. Sanders, Barbara Holzer, Irene Zimpernikc, Eduardo López-Collazo, Patricia Muñoz, Paloma Rueda, Carmen Vela

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Abstract

Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

Originalsprache	Englisch
Aufsatznummer	115650
Seiten (von - bis)	115650
Seitenumfang	1
Fachzeitschrift	Diagnostic Microbiology and Infectious Disease
Jahrgang	102
Ausgabenummer	4
DOIs	https://doi.org/10.1016/j.diagmicrobio.2022.115650
Publikationsstatus	Veröffentlicht - 4 Apr. 2022
Extern publiziert	Ja

ÖFOS 2012 - Österreichischen Systematik der Wissenschaftszweige

304005 Medizinische Biotechnologie

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Zugriff auf Dokument

10.1016/j.diagmicrobio.2022.115650

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Fresco-Taboada, A., García-Durán, M., Aira, C., López, L., Sastre, P., Hoek, L. V. D., Gils, M. J. V., Brouwer, P. J. M., Sanders, R. W., Holzer, B., Zimpernikc, I., López-Collazo, E., Muñoz, P., Rueda, P., & Vela, C. (2022). Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. Diagnostic Microbiology and Infectious Disease, 102(4), 115650. Artikel 115650. https://doi.org/10.1016/j.diagmicrobio.2022.115650

@article{86d991d25da2468096d2f03ed2aed006,

title = "Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination",

abstract = "Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.",

keywords = "SARS-CoV-2, COVID-19, Vaccination, Serology, RBD, Spike protein, Spike Glycoprotein, Coronavirus, Humans, Sensitivity and Specificity, Antibodies, Viral, COVID-19/diagnosis",

author = "Alba Fresco-Taboada and Marga Garc{\'i}a-Dur{\'a}n and Cristina Aira and Lissett L{\'o}pez and Patricia Sastre and Hoek, {Lia van der} and Gils, {Marit J. van} and Brouwer, {Philip J.M.} and Sanders, {Rogier W.} and Barbara Holzer and Irene Zimpernikc and Eduardo L{\'o}pez-Collazo and Patricia Mu{\~n}oz and Paloma Rueda and Carmen Vela",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = apr,

day = "4",

doi = "10.1016/j.diagmicrobio.2022.115650",

language = "English",

volume = "102",

pages = "115650",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "4",

}

Fresco-Taboada, A, García-Durán, M, Aira, C, López, L, Sastre, P, Hoek, LVD, Gils, MJV, Brouwer, PJM, Sanders, RW, Holzer, B, Zimpernikc, I, López-Collazo, E, Muñoz, P, Rueda, P & Vela, C 2022, 'Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination', Diagnostic Microbiology and Infectious Disease, Jg. 102, Nr. 4, 115650, S. 115650. https://doi.org/10.1016/j.diagmicrobio.2022.115650

Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. / Fresco-Taboada, Alba; García-Durán, Marga; Aira, Cristina et al.
in: Diagnostic Microbiology and Infectious Disease, Jahrgang 102, Nr. 4, 115650, 04.04.2022, S. 115650.

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

TY - JOUR

T1 - Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination

AU - Fresco-Taboada, Alba

AU - García-Durán, Marga

AU - Aira, Cristina

AU - López, Lissett

AU - Sastre, Patricia

AU - Hoek, Lia van der

AU - Gils, Marit J. van

AU - Brouwer, Philip J.M.

AU - Sanders, Rogier W.

AU - Holzer, Barbara

AU - Zimpernikc, Irene

AU - López-Collazo, Eduardo

AU - Muñoz, Patricia

AU - Rueda, Paloma

AU - Vela, Carmen

PY - 2022/4/4

Y1 - 2022/4/4

N2 - Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

AB - Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

KW - SARS-CoV-2

KW - COVID-19

KW - Vaccination

KW - Serology

KW - RBD

KW - Spike protein

KW - Spike Glycoprotein, Coronavirus

KW - Humans

KW - Sensitivity and Specificity

KW - Antibodies, Viral

KW - COVID-19/diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85125115958&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2022.115650

DO - 10.1016/j.diagmicrobio.2022.115650

M3 - Article

C2 - 35218991

SN - 0732-8893

VL - 102

SP - 115650

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 4

M1 - 115650

ER -